Construction of a survival nomogram for gastric cancer based on the cancer genome atlas of m6A-related genes

Abstract

Objective: Based on TCGA database, a prediction model for 1-, 3-, and 5-year overall survival rates of gastric cancer (GC) patients was constructed by analyzing the critical risk factors affecting the prognosis of gastric cancer patients.Method: Clinicopathological features as well as gene signature of GC patients were obtained from TCGA database. Patients were randomly divided into a training cohort and an internal validation cohort. Independent predictors of GC prognosis were analyzed by univariate and multivariate Cox analyses to construct nomogram. The accuracy and reliability of the model was further validated by calibration curves, ROC curves, and C-indexes, and the clinical utility of the model was analyzed by decision analysis curves.Result: Age, sex, N stage, M stage, METTL16, RBM15, FMR1, IGFBP1, and FTO were significantly associated with the prognosis of GC patients, and these predictors were further included in the construction of nomogram. The C-indexes for the training cohort and validation set were 0.735 and 0.688, respectively. The results of the ROC curve analysis indicated that the area under the curve (AUC) exceeded 0.6 in training and validation sets at 1, 3, and 5 years.Conclusion: We have constructed and validated a nomogram that provides individual survival condition prediction for GC patients. The prognostic model integrating gene signatures and clinicopathological characteristics would help clinicians determine the prognosis of patients with GC and develop individualized treatment plans.

Glutamine metabolism genes prognostic signature for stomach adenocarcinoma and immune infiltration: potential biomarkers for predicting overall survival

“…The management of STAD is a critical clinical issue due to the rapid disease progression and dismal prognosis. A lack of potent tumor-killing initiators and selective tumor-targeting therapeutic medications limits the efficiency of precision medicine for STAD ( 24 ). A recent study discovered that alterations to the mechanism of programmed tumor cell death may enhance STAD’s targeted therapeutic benefits ( 25 ).…”

Constructing and validating of m6a-related genes prognostic signature for stomach adenocarcinoma and immune infiltration: Potential biomarkers for predicting the overall survival

“…The clinical management of STAD is a serious clinical concern due to rapid disease progression and poor prognosis. The level of precision medicine for STAD is hampered by a lack of effective tumor-killing initiators and selective tumor-targeting therapeutic medicines ( 23 ). A recent study found that alterations of the mechanism of programmed tumor cell death may potentiate the targeted therapeutic impact of STAD ( 24 ).…”

SPOC domain proteins in health and disease

“…On the other hand, aberrant RBM15-driven m 6 A deposition may stabilize certain oncogenic transcripts by connecting them to IGF2BP1-3 m 6 A readers that promote transcript stability and are overexpressed in different cancer types (Li et al 2019;Cai et al 2021;Wang et al 2021). The connection between m 6 A, RBM15/B, and cancer has received increased attention in recent years; however, further research is necessary to clarify the exact roles that RBM15/B-driven m 6 A deposition plays in tumorigenesis and whether RBM15/B expression levels could be used as biomarkers (Li et al 2019;Wang et al 2022). TCGA data for RBM15 and RBM15B show different mutations dispersed over the entire genes (Fig.…”